[Phe4]somatostatin: a potent, selective inhibitor of growth hormone release.

Authors:
  • CMC A Meyers
    C A Meyers
  • DCD H Coy
    D H Coy
  • WMW A Murphy
    W A Murphy
  • TRT W Redding
    T W Redding
  • AAA Arimura
    A Arimura
  • ASA V Schally
    A V Schally
Publisher website
Google Scholar
Abstract
[Phe4]Somatostatin was twice as active as somatostatin (SS) in suppressing rat growth hormone [GH] release in vitro but had only weak activity toward inhibition of insulin and glucagon release in vivo. The ability of this analog to inhibit GH release more actively than SS was confirmed in vivo by 2 separately designed bioassays. Further structure/activity studies of position 4 were carried out with [Glu4]SS,[Thr4]SS and des-Lys4-SS, all of which had negligible inhibiting activity in the pituitary and pancreas. The strikingly selective activity of [Phe4]SS suggests a fundamental difference in the SS receptors of pituitary and pancreas, and the normal side-chain basicity of position 4 appears to be more important for action in pancreas than in pituitary. [Phe4]SS has properties that may be useful in the development of agents for the treatment of acromegaly or other disorders associated with increased GH levels.

This publication has 9 references indexed in Scilit: